To view this email as a web page, click here

Subscribe

Advertise

 

 

 

 

 

 

June 01, 2018

Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications.

Featured Story

Ambien made me racist? No way, Sanofi tells Roseanne, and its tweet goes viral

The head of North American communications for Sanofi woke up Wednesday to the news that actress Roseanne Barr had blamed her recent racist tweet on the use of the company's insomnia drug, Ambien. But Sanofi wasn’t having it.

Top Stories Of The Week

Former Novartis U.S. oncology head Bill Hinshaw jumps ship to metabolic startup

Novartis continues its hemorrhaging of executives seeking new careers at smaller, younger biotechs as its EVP and head of U.S. oncology Bill Hinshaw takes the reins at Axcella Health.

Biogen poaches Pfizer dealmaker Dan Karp for stepped-up M&A push

Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it recruited veteran Dan Karp in a revamp of its BD and corporate strategy team.

Venter to leave Human Longevity as turnover at the top continues

Craig Venter, Ph.D., is leaving Human Longevity Inc. Venter’s decision to step down as CEO and return to research at the J. Craig Venter Institute continues the turnover at the top of HLI, which has now lost two CEOs and a CMO in the past six months.

Roche's Tecentriq grabs badly needed lung cancer win to keep Keytruda in its sights

Looks like Merck’s Keytruda could get some company in the lung cancer chemo-combo department. On Monday, nemesis Roche said its Tecentriq, in combination with carboplatin and Celgene’s Abraxane, had topped solo chemo at helping previously untreated patients live longer and at keeping disease at bay.

Novartis' under-pressure Sandoz unit offloads Quebec plant to fast-growing Avara

Novartis has been looking to jettison some assets in its North American generics business, but as it turns out, a manufacturing facility in Canada will be sold off first. Its buyer, Avara, will add the Sandoz plant to a series of Big Pharma pickups over the past year.

WuXi AppTec warns traders to cool off after 6-fold stock price increase in 3 weeks

WuXi AppTec reminded traders to consider the risks of investing in CROs after its stock price increased by the daily maximum of 10% for 15 straight trading sessions following its Shanghai IPO earlier this month. That vaulted its market cap to over $21 billion.

Gut-liver connection uncovers new avenues for cancer treatment

A team at the National Cancer Institute has discovered how bacteria in the gut affect antitumor immune responses in the liver, a connection that could be exploited to find new therapies for liver cancer.

Titan, Braeburn end licensing deal for implanted drug for opioid addicts

Titan Pharmaceuticals and Braeburn are parting ways over an opioid treatment licensing deal inked in 2012.

Doctors can change vaccine-hesitant parents' minds by being persistent: study

A new study shows that when doctors were persistent in encouraging HPV vaccination, 94% of children were vaccinated.

Enrollment Showcase

SBMI Now Offering an Online Graduate Program in Bioinformatics

UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics.

Resources

[Whitepaper] Is the pharma business model ready for precision medicine?

Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare.

[Whitepaper] Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure.

[Whitepaper] A Simpler Approach to RBM in Clinical Trial Management

Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation.

[Whitepaper] Five Tracking Spreadsheets it’s Time for Regulatory to Retire

Find out how to eliminate regulatory’s tracking spreadsheets for good.

[Whitepaper] Regulatory Transformation at UCB

UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off.

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

.